ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0141

Antibody Response to COVID-19 Vaccine in Peritoneal Dialysis (PD) Patients: A Single-Center Study

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Rahim, Shab E Gul, Weill Cornell Medicine, New York, New York, United States
  • Tummalapalli, Sri Lekha, Weill Cornell Medicine, New York, New York, United States
  • Stryjniak, Gabriel, Weill Cornell Medicine, New York, New York, United States
  • Gerardine, Supriya, Weill Cornell Medicine, New York, New York, United States
  • Srivatana, Vesh, Weill Cornell Medicine, New York, New York, United States
Background

In initial published reports of dialysis patients, response to COVID-19 vaccination tends to be lower as compared to general population. To date, these studies were primarily focused on hemodialysis (HD) patients. We studied the factors associated with COVID-19 vaccine humoral response in PD patients.

Methods

Our research setting was a single-center academic institution in New York City. We included patients on PD who received the COVID-19 vaccine. Response was assessed at a median of 4 weeks after completing the full vaccination series by measuring semiquantitative COVID-19 spike protein total antibody (Ab) level using a chemiluminescent sandwich immunoassay. Chi-squared tests for categorical variables and Wilcoxon rank-sum tests for continuous variables were used to compare characteristics among patients who did and did not have an Ab response.

Results

Of 111 patients on PD in our center, 64 (58%) received COVID-19 vaccine as of April 2021 and had Ab levels checked. A total of 60/64 (94%) of patients had a positive Ab response and 4/64 (6%) did not mount a response. IgG levels in positive responders were a median of 11.5 (interquartile range, 1.9 – 20). Lower Kt/V was associated with a positive Ab response (p = 0.045) and type of vaccine was associated with an Ab response (p = 0.028). Age, BMI, diabetes, hypertension, lymphocyte count, or residual Kt/V were not statistically significantly associated with Ab response to the vaccine (Table 1).

Conclusion

In conclusion, the vast majority of patients on PD developed positive Ab response to the COVID-19 vaccine. While a small sample size limited our statistical power, our results show promising COVID-19 vaccine effectiveness among patients on PD.